Clinical Trials
12 trialsNCT05054543 2025-06-27
Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML
Apollomics Inc.
Phase 3 Terminated
NCT02641639 2025-03-24
FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer
Mateon Therapeutics
Phase 2/3 Terminated
NCT04571645 2024-04-15
AML
Jazz Pharmaceuticals
Phase 3 Terminated
NCT04426201 2024-04-11
ILIAD-7-US-O
Revimmune
Phase 2 Terminated
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT04095858 2023-02-08
CATHY
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3 Terminated
NCT03241810 2020-09-02
SHERBOC
Elevation Oncology
Phase 2 Terminated
NCT02258464 2020-08-10
Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer
Bayer
Phase 2 Terminated
NCT02049151 2017-08-23
START2
EMD Serono
Phase 3 Terminated
NCT01015443 2016-10-26
INSPIRE
Merck KGaA, Darmstadt, Germany
Phase 3 Terminated
NCT01083615 2016-10-12
A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Achieve Life Sciences
Phase 3 Terminated
NCT00925548 2014-07-24
STRIDE
EMD Serono
Phase 3 Terminated